Provera for Period Delay: Not an FDA-Approved Indication
Provera (medroxyprogesterone acetate) is not FDA-approved for menstrual delay in healthy women, and prescribing it for this purpose would be off-label use. The FDA-approved indications for Provera are limited to treating absent or abnormal uterine bleeding and reducing endometrial cancer risk in postmenopausal women on estrogen therapy 1.
FDA-Approved Uses of Provera
According to the FDA drug label, Provera is indicated for 1:
- Treatment of absent menstrual periods (secondary amenorrhea) - doses of 5-10 mg daily for 5-10 days
- Treatment of abnormal uterine bleeding - doses of 5-10 mg daily for 5-10 days
- Endometrial protection in postmenopausal women using estrogen - doses of 5-10 mg daily for 12-14 days per month
Why Period Delay Is Not Included
The mechanism of Provera involves treating conditions where progesterone levels have dropped, not manipulating normal menstrual cycles for convenience. The FDA label explicitly states it is for women who "stop having regular menstrual periods or who begin to have irregular menstrual periods" due to progesterone deficiency 1.
Alternative Approaches for Period Delay
If a patient desires menstrual manipulation:
- Combined hormonal contraceptives (CHCs) used in extended or continuous regimens are the appropriate evidence-based option 2
- CHCs can be initiated anytime if reasonably certain the patient is not pregnant, with backup contraception needed if started >5 days after menses 2
- Extended/continuous CHC regimens are specifically addressed in current CDC guidelines for managing bleeding patterns 2
Critical Safety Considerations
The FDA label contains a black box warning that progestins should not be used with estrogens to prevent cardiovascular disease, and their use may increase risks of 1:
- Heart attacks and strokes
- Blood clots
- Breast cancer
- Dementia (in women ≥65 years)
Recent evidence (2024-2025) demonstrates that depot medroxyprogesterone acetate (DMPA) increases meningioma risk, with a relative risk of 2.43 for intracranial meningioma, particularly with >4 years of exposure or initiation after age 31 3, 4. While this data pertains to injectable DMPA rather than oral Provera, it raises concerns about prolonged progestin exposure.
Clinical Bottom Line
Do not prescribe Provera for period delay. This is off-label use without supporting evidence for efficacy or safety in this context. Instead, counsel patients on FDA-approved CHC extended regimens if they desire menstrual manipulation. If a patient specifically requests Provera for an FDA-approved indication (absent periods or abnormal bleeding), ensure proper evaluation to rule out pregnancy, underlying pathology, and contraindications before prescribing 1.